Ticlopidine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ticlopidine
Ticlopidine.svg
Ticlopidine ball-and-stick.png
Systematic (IUPAC) name
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
Clinical data
Trade names Ticlid
AHFS/Drugs.com monograph
MedlinePlus a695036
Pregnancy cat.
Legal status
?
Routes Oral
Pharmacokinetic data
Bioavailability >80%
Protein binding 98%
Metabolism Hepatic
Half-life
  • 12 hours (single dose)
Excretion Renal and fecal
Identifiers
CAS number 55142-85-3 YesY
ATC code B01AC05
PubChem CID 5472
DrugBank DB00208
ChemSpider 5273 YesY
UNII OM90ZUW7M1 YesY
KEGG D08594 YesY
ChEBI CHEBI:9588 YesY
ChEMBL CHEMBL833 YesY
Chemical data
Formula C14H14ClNS 
Mol. mass 263.786 g/mol
 YesY (what is this?)  (verify)

Ticlopidine (trade name Ticlid) is an antiplatelet drug in the thienopyridine family. Like the newer drug clopidogrel, it is an adenosine diphosphate (ADP) receptor inhibitor. It is used in patients in whom aspirin is not tolerated, or in whom dual antiplatelet therapy is desirable. Because it has been reported to increase the risk of thrombotic thrombocytopenic purpura (TTP) and neutropenia, its use has largely been supplanted by clopidogrel, which is thought to have a much lower hematologic risk. Its niche role as an alternative in those patients who do not tolerate clopidogrel was superseded by Ticagrelor and Prasugrel. The usual dose is 250 mg twice daily by the oral route.

Action[edit]

  • Inhibits platelet aggregation by altering the function of platelet membranes by blocking ADP receptors. This prevents the conformational change of glycoprotein IIb/IIIa which allows platelet binding to fibrinogen.
  • Prolongs bleeding time.
  • Decreased incidence of stroke in high-risk patients.

Contraindications[edit]

Precautions[edit]

and others